Balchem ( (BCPC) ) has released its Q4 earnings. Here is a breakdown of the information Balchem presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Balchem Corporation, a leader in the human nutrition and health, animal nutrition and health, and specialty products sectors, reported robust financial results for the fourth quarter and full year of 2024. The company, known for its innovative solutions in these sectors, has demonstrated significant growth in both revenue and earnings.
Balchem’s fourth-quarter performance was marked by record net sales of $240 million and a 26% increase in net earnings compared to the previous year. The company also achieved a record adjusted EBITDA of $62.8 million, indicating a strong financial position. For the full year 2024, Balchem recorded net sales of $953.7 million, with a 3.4% increase from the previous year and notable growth in its core segments.
Key highlights include a 4.9% increase in quarterly net sales and a 13.4% rise in adjusted EBITDA compared to the same period last year. The Human Nutrition & Health segment led the growth with a 6.8% increase in sales, while the Animal Nutrition & Health and Specialty Products segments also showed positive results. Balchem’s strategic focus on strengthening its balance sheet was evident as the company reduced its debt by $119.6 million over the year.
Looking ahead, Balchem’s management remains optimistic about future growth opportunities. With a strong financial foundation and a focus on strategic initiatives, the company is well-positioned to continue delivering value to its shareholders in 2025 and beyond.
